The Switch 2's latest update brings support for two great games.
See all Stories Posted Jul 15, 2025 at 11:18 PM UTC
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Piper sees H20 ban hurting Nvidia sales by $8B in July quarter
Piper Sandler keeps an Overweight rating on Nvidia (NVDA) after the company said it expects to be granted licenses to resume H20 chip sales to China. During the April quarter, the company posted $4.6B in sales for H20 and left an additional $2.5B on the table due to the ban, the analyst tells investors in a research note. Piper says the estimated impact from the ban in the July quarter was around $8B in sales. It suspects strong demand for these chips would have continued should the ban not been in place. The merchant artificial intelligence companies alongside Nvidia, namely Micron (MU) and AMD (AMD), would benefit from the lifting of this ban, contends Piper. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on NVDA: Disclaimer & DisclosureReport an Issue Nvidia price target raised to $195 from $160 at DZ Bank Notable open interest changes for July 15th Video: Nvidia, AMD jump as shipments to China expected to resume Eaton, Nvidia collaborate on power infrastructure in artificial intelligence Nvidia price target raised to $235 from $205 at Melius Research Sign in to access your portfolio
Yahoo
12 minutes ago
- Yahoo
Jefferies Reiterates a Buy Rating on LivaNova PLC (LIVN) With a $79 PT
LivaNova PLC (NASDAQ:LIVN) is one of the best undervalued medical device stocks to buy now. On June 6, Jefferies analyst Matthew Taylor maintained a Buy rating on LivaNova PLC (NASDAQ:LIVN) and set a price target of $79.00. The analyst based the rating on the company's strong growth potential, stating that it is undergoing a solid product cycle, especially with the Essenz upgrade. A close-up of a medical device used for therapeutic solutions in a world-class hospital. Taylor anticipates the upgrade to bring a considerable revenue boost through a rise in average selling prices as the replacement cycle progresses. Another factor highlighting the company's competitive edge is its expansion in the oxygenator market, with expanding production capacity and a growing market share. The analyst also reasoned that LivaNova PLC (NASDAQ:LIVN) has a strategic focus on internal execution for the commercialization of its Obstructive Sleep Apnea (OSA) solutions and reported promising data from its Depression Treatment Device (DTD) pipeline, factors that further support the optimistic rating. LivaNova PLC (NASDAQ:LIVN) is a global medical technology company that develops and delivers therapeutic solutions to benefit healthcare systems, patients, and healthcare professionals. The company's operations are divided into Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. While we acknowledge the potential of LIVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
12 minutes ago
- Yahoo
Cantor Fitzgerald Initiates Coverage of Bioventus (BVS) with an Overweight Rating
Bioventus Inc. (NASDAQ:BVS) is one of the best undervalued medical device stocks to buy now. On July 7, Cantor Fitzgerald analyst Ross Osborn initiated coverage of Bioventus Inc. (NASDAQ:BVS) with an Overweight rating and $12 price target. A doctor repairing a foot and ankle injury using the latest sports medicine techniques. The company reported a 4.3% decline in its worldwide revenue for fiscal Q1 2025 to $123.9 million from $129.5 million in the same period last year. The drop reflects the effects of the previous year's divestiture of the Advanced Rehabilitation Business. Bioventus Inc. (NASDAQ:BVS) also reported a 5.0% growth in organic revenue in the quarter, attributed to positive organic growth across all three businesses. Global revenue in Paint Treatments rose 3.9% to $58.9 million, driven by double-digit growth in demand for Durolane. Durolane is a single-injection hyaluronic acid therapy that targets knee osteoarthritis. Similarly, Surgical Solutions also underwent a 7.0% growth in global revenue in the quarter to $45.2 million, attributed to double-digit growth from Ultrasonics due to strong capital equipment purchases in the US. Bioventus Inc. (NASDAQ:BVS) is a medical technology company that develops and commercializes proprietary orthobiologic products to treat musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. While we acknowledge the potential of BVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Se produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información
